Diseño de un plan estratégico en la empresa Fianza Crédito Inmobiliario de Santander S.A.

113 Páginas.En un mundo en permanente mutación en que las fuerzas del cambios trastocan constantemente, la inercia y los hábitos organizacionales; se ve la necesidad de que las organizaciones tengan muy claramente definido y puedan aplicar la estrategia planeada, por lo cual el presente proyecto de investigación se enfocará en el estudio y análisis de posibles líneas de actuaciones futuras, a través de la utilización de herramientas administrativas, estructuradas, con método de estudio mixto a fin de no solo conocer los resultados cuantitativos que aportará, si no los efectos cualitativos que tendrá como resultado la aplicación de la prospectiva estratégica. Por consiguiente se plantea el problema objeto de estudio, el objetivo general y los objetivos específicos que se pretenden alcanzar, el análisis del diagnóstico estratégico, análisis de futuros probables y posibles, Juego de Actores, formulación e implementación de la estrategia diseñada para la compañía Fianzacredito Inmobiliario de Santander S.A

Genotyping squamous cell lung carcinoma in Colombia (Geno1.1-CLICaP)

Background: Lung cancer is a public health problem, and squamous cell carcinoma (SCC) is the second most prevalent subtype of this neoplasm. Compared to other subtypes, including adenocarcinoma, SCC is less well understood in terms of molecular pathogenesis, limiting therapeutic options among targeted agents approved for other disease subgroups. In this study, we sought to characterize the SCC genomic profile using a validated Next Generation Sequencing (NGS) platform. Methods: The comprehensive NGS assay (TruSight Tumor 170) was used in order to target the full coding regions of 170 cancer-related genes on SCC samples. PD-L1 expression in tumor cells (TCs) was assessed using clone 22C3 (Dako). Clinical outcomes were correlated with molecular profile, including progression free survival (PFS), overall response rate (ORR), and overall survival (OS). Results: A total of 26 samples were included, median age was 67 years (r, 33–83) and 53.8% were men. Tobacco consumption was identified in all subjects (mean 34-year package). For first-line treatment 80.8% of patients received cisplatin or carboplatin plus gemcitabine. In terms of molecular profile, we identified a high prevalence of inactivating mutations in TP53 (61.5%), PIK3CA (34.6%), MLL2 (34.6%), KEAP1 (38.4%), and NOTCH1 (26.9%). PD-L1 expression ranged from negative, 1, 2–49, and ≥50% in 23.1, 38.5, 26.9, and 11.5%, respectively. Interestingly, the genetic alterations did not have an effect in PFS, OS or ORR in this study. However, PDL1 expression was higher among those who had mutations in TP53 (p = 0.037) and greater expression of PDL1 was related to PIK3CA alterations (p = 0.05). Conclusions: The genomic profile of SCC encompasses important genes including TP53, PIK3CA and KEAP1. TP53 mutations could be associated with PDL1 expression, generating hypothesis regarding specific treatment options